Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery

Ju Hwan Park, Hyun Jong Cho, Hong Yeol Yoon, In Soo Yoon, Seung Hak Ko, Jae Seong Shim, Jee Hyun Cho, Jae Hyung Park, Kwang Meyung Kim, Ick Chan Kwon, Dae Duk Kim

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.

Original languageEnglish
Pages (from-to)98-108
Number of pages11
JournalJournal of Controlled Release
Volume174
Issue number1
DOIs
Publication statusPublished - 2014 Jan 28
Externally publishedYes

Fingerprint

Hyaluronic Acid
Liposomes
Pharmaceutical Preparations
Doxorubicin
Neoplasms
Ceramides
Magnetic Resonance Imaging
Gadolinium DTPA
Contrast Media
Pharmacokinetics

Keywords

  • Doxorubicin
  • Hyaluronic acid-ceramide
  • Hybrid nanostructure
  • Lipid
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Park, J. H., Cho, H. J., Yoon, H. Y., Yoon, I. S., Ko, S. H., Shim, J. S., ... Kim, D. D. (2014). Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. Journal of Controlled Release, 174(1), 98-108. https://doi.org/10.1016/j.jconrel.2013.11.016

Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. / Park, Ju Hwan; Cho, Hyun Jong; Yoon, Hong Yeol; Yoon, In Soo; Ko, Seung Hak; Shim, Jae Seong; Cho, Jee Hyun; Park, Jae Hyung; Kim, Kwang Meyung; Kwon, Ick Chan; Kim, Dae Duk.

In: Journal of Controlled Release, Vol. 174, No. 1, 28.01.2014, p. 98-108.

Research output: Contribution to journalArticle

Park, JH, Cho, HJ, Yoon, HY, Yoon, IS, Ko, SH, Shim, JS, Cho, JH, Park, JH, Kim, KM, Kwon, IC & Kim, DD 2014, 'Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery', Journal of Controlled Release, vol. 174, no. 1, pp. 98-108. https://doi.org/10.1016/j.jconrel.2013.11.016
Park, Ju Hwan ; Cho, Hyun Jong ; Yoon, Hong Yeol ; Yoon, In Soo ; Ko, Seung Hak ; Shim, Jae Seong ; Cho, Jee Hyun ; Park, Jae Hyung ; Kim, Kwang Meyung ; Kwon, Ick Chan ; Kim, Dae Duk. / Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. In: Journal of Controlled Release. 2014 ; Vol. 174, No. 1. pp. 98-108.
@article{b10c396a78474fe29b85e38ec2978d54,
title = "Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery",
abstract = "Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.",
keywords = "Doxorubicin, Hyaluronic acid-ceramide, Hybrid nanostructure, Lipid, Magnetic resonance imaging",
author = "Park, {Ju Hwan} and Cho, {Hyun Jong} and Yoon, {Hong Yeol} and Yoon, {In Soo} and Ko, {Seung Hak} and Shim, {Jae Seong} and Cho, {Jee Hyun} and Park, {Jae Hyung} and Kim, {Kwang Meyung} and Kwon, {Ick Chan} and Kim, {Dae Duk}",
year = "2014",
month = "1",
day = "28",
doi = "10.1016/j.jconrel.2013.11.016",
language = "English",
volume = "174",
pages = "98--108",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery

AU - Park, Ju Hwan

AU - Cho, Hyun Jong

AU - Yoon, Hong Yeol

AU - Yoon, In Soo

AU - Ko, Seung Hak

AU - Shim, Jae Seong

AU - Cho, Jee Hyun

AU - Park, Jae Hyung

AU - Kim, Kwang Meyung

AU - Kwon, Ick Chan

AU - Kim, Dae Duk

PY - 2014/1/28

Y1 - 2014/1/28

N2 - Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.

AB - Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.

KW - Doxorubicin

KW - Hyaluronic acid-ceramide

KW - Hybrid nanostructure

KW - Lipid

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84888996200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888996200&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2013.11.016

DO - 10.1016/j.jconrel.2013.11.016

M3 - Article

C2 - 24280260

AN - SCOPUS:84888996200

VL - 174

SP - 98

EP - 108

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -